The enormous technology conglomerate Softbank is continuing its spending spree, this time investing $1.1 billion into biotech firm Roivant Sciences. The drugmaker is currently developing seven neurological therapies and several treatments for rare diseases, among others. It’s the first time that Softbank has dipped into its $93 billion Vision Fund, which includes cash from Saudi Arabia, to support a drugmaker. Roivant’s CEO, Vivek Ramaswamy, tells Endpoints that the funding injection won’t all be used for regular biotech ideas: instead, some of it will be funnelled into what he calls “new technologies that can improve a biotech’s efficiency.”
Softbank is on a huge spending spree right now. In the past year, it has acquired the British chip designer ARM, invested $4 billion into chipmaker Nvidia, turned the London-based simulation startup Improbable into a unicorn, and gobbled up the robot maker Boston Dynamics. Next stop, drug tech.
Here’s how a Twitter engineer says it will break in the coming weeks
One insider says the company’s current staffing isn’t able to sustain the platform.
Technology that lets us “speak” to our dead relatives has arrived. Are we ready?
Digital clones of the people we love could forever change how we grieve.
How to befriend a crow
I watched a bunch of crows on TikTok and now I'm trying to connect with some local birds.
Starlink signals can be reverse-engineered to work like GPS—whether SpaceX likes it or not
Elon said no thanks to using his mega-constellation for navigation. Researchers went ahead anyway.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.